跳至主要内容
临床试验/DRKS00032351
DRKS00032351招募中不适用

German prospective registry for patients with chronic myeloid leukemia (CML) previously treated with =2 TKIs switched to another TKI (ASCiminib or ANY ATP-competitive TKI) - ASCANY

Ruprecht-Karls-Universität Heidelberg0 个研究点目标入组 300 人开始时间: 2024年3月6日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Ph+ or BCR::ABL1 -fusion gene positive CML in chronic phase
  • 2. Prior treatment with = 2 TKIs
  • 3. Decision of the treating physician to switch to a TKI approved for third line CML treatment; the TKI has already been selected by the physician at time of enrollment
  • 4. Switch due to warning or failure (adapted from the 2020 ELN recommendations ) or due to intolerance to the most recent TKI therapy
  • 5. Age = 18 years at the time of change to a new TKI-treatment
  • 6. Signed informed consent prior to participation in this registry

排除标准

  • Existing T315I mutation

研究者

相似试验

German prospective registry for patients with... | 临床试验